You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

List of Excipients in API regorafenib


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing regorafenib

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Bayer HealthCare Pharmaceuticals Inc STIVARGA regorafenib 50419-171 CELLULOSE, MICROCRYSTALLINE 2031-04-08
Bayer HealthCare Pharmaceuticals Inc STIVARGA regorafenib 50419-171 CROSCARMELLOSE SODIUM 2031-04-08
Bayer HealthCare Pharmaceuticals Inc STIVARGA regorafenib 50419-171 FERRIC OXIDE RED 2031-04-08
Bayer HealthCare Pharmaceuticals Inc STIVARGA regorafenib 50419-171 FERRIC OXIDE YELLOW 2031-04-08
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Sign Up

Detailed excipient profiles for regorafenib

Excipient focus: CELLULOSE, MICROCRYSTALLINE

Excipient focus: CROSCARMELLOSE SODIUM

Excipient focus: FERRIC OXIDE RED

Excipient focus: FERRIC OXIDE YELLOW

Excipient focus: LECITHIN, SOYBEAN

Excipient focus: MAGNESIUM STEARATE

Excipient focus: POLYETHYLENE GLYCOL 3350

Excipient focus: POLYVINYL ALCOHOL

Excipient focus: POVIDONE

Excipient focus: SILICON DIOXIDE

Excipient focus: TALC

Excipient focus: TITANIUM DIOXIDE

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
 NCE-1 Patent Challenge Dates 2024 - 2025
 Trigger-based marketing for the life sciences
 Get DrugPatentWatch Business Intelligence Reports at Amazon.com
 DrugChatter - AI-based answers to questions about drugs
 RxJam - Digital Marketing for Life Sciences
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group